<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-29386" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Splenomegaly</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chapman</surname>
            <given-names>Jennifer</given-names>
          </name>
          <aff>Lahey Health Systems</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Goyal</surname>
            <given-names>Amandeep</given-names>
          </name>
          <aff>University of Kansas Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Azevedo </surname>
            <given-names>Alexandre M.</given-names>
          </name>
          <aff>Hospital Santa Marcelina</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jennifer Chapman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Amandeep Goyal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Alexandre Azevedo declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-29386.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Splenomegaly is defined as the enlargement of the spleen measured by size or weight. The spleen plays a significant role in hematopoiesis and immunosurveillance. The major functions of the spleen include clearance of abnormal erythrocytes, removal of microorganisms and antigens, as well as the synthesis of immunoglobulin G (IgG). The spleen also synthesizes the immune system peptides properdin and tuftsin. Approximately one-third of circulating platelets are stored in the spleen. The normal weight of the adult spleen is 70 g to 200 g, spleen weight of 400 g to 500 g indicates splenomegaly spleen weight greater than 1000 g is definitive of massive splenomegaly. This activity reviews the causes, evaluation, and management of splenomegaly and highlights the role of the interprofessional team in managing patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of splenomegaly.</p></list-item><list-item><p>Describe the typical history and physical exam findings in a patient with splenomegaly.</p></list-item><list-item><p>Outline the treatment and management options for splenomegaly.</p></list-item><list-item><p>Review interprofessional team strategies for improving care coordination and communication to advance splenomegaly and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29386&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29386">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-29386.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Splenomegaly is defined as the enlargement of the spleen measured by weight or size.&#x000a0;The spleen plays a significant role in hematopoiesis and immunosurveillance. The&#x000a0;major functions of the spleen&#x000a0;include clearance of senescent and abnormal erythrocytes and their remnants, opsonized platelets and white blood cells, and removal of microorganisms and antigens. The spleen also serves as a secondary lymphoid organ and is the site for the maturation and storage of T and B lymphocytes, playing an important role in the synthesis of&#x000a0;immunoglobulin G (IgG) by mature B-lymphocytes upon interaction with the T-lymphocytes.&#x000a0; The spleen also synthesizes&#x000a0;the immune system peptides properdin and tuftsin. Approximately one-third of&#x000a0;circulating platelets are stored in the spleen. The normal position&#x000a0;of the spleen is within the peritoneal cavity in the left upper quadrant&#x000a0;adjacent&#x000a0;to ribs 9 through 12. The normal-sized spleen abuts the stomach, colon, and left kidney.</p>
        <p>The size and weight of the spleen may vary and correlate with the weight, height, and sex of an individual, with larger spleen size seen in men compared to women and in heavier or taller individuals.&#x000a0;A normally sized spleen measures up to 12 cm in craniocaudal length.&#x000a0; A&#x000a0;length of 12 cm to 20 cm indicates splenomegaly and a length greater than 20 cm is&#x000a0;definitive of massive splenomegaly. The normal weight of the adult spleen is 70 g to 200 g; a spleen weight of 400 g to 500 g indicates splenomegaly and a spleen weight greater than 1000 g is definitive of massive splenomegaly. The normal-sized&#x000a0;spleen is usually not palpable in adults. However, it may be palpable due to variations in body habitus and chest wall anatomy. Splenomegaly may be diagnosed clinically or radiographically using ultrasound, CT imaging, or MRI.&#x000a0; Splenomegaly may be a transient condition due to acute illness or may&#x000a0;be due to&#x000a0;serious underlying acute or chronic pathology.<xref ref-type="bibr" rid="article-29386.r1">[1]</xref><xref ref-type="bibr" rid="article-29386.r2">[2]</xref><xref ref-type="bibr" rid="article-29386.r3">[3]</xref></p>
      </sec>
      <sec id="article-29386.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>There are several potential causes of splenomegaly.&#x000a0;</p>
        <list list-type="order">
          <list-item>
            <p>Liver disease (cirrhosis, hepatitis): Parenchymal liver disease causes&#x000a0;increased vascular pressure leading to an increase in spleen size.</p>
          </list-item>
          <list-item>
            <p>Hematologic malignancies&#x000a0;(lymphomas, leukemias, myeloproliferative disorders): Neoplastic cells cause infiltration of the spleen leading to splenomegaly.</p>
          </list-item>
          <list-item>
            <p>Venous thrombosis (portal or hepatic vein thrombosis): This leads to an increase in vascular pressure leading to splenomegaly.</p>
          </list-item>
          <list-item>
            <p>Splenic congestion&#x000a0;(venous thrombosis, portal hypertension, congestive heart failure).</p>
          </list-item>
          <list-item>
            <p>Cytopenias (autoimmune hemolytic anemia, immune-mediated neutropenia, Felty syndrome): Immune-mediated destruction of red blood cells, white blood cells, or platelets lead to functional splenomegaly.</p>
          </list-item>
          <list-item>
            <p>Splenic sequestration (pediatric sickle cell disease, hemolytic anemias, thalassemias).</p>
          </list-item>
          <list-item>
            <p>Acute or chronic infection (bacterial endocarditis, infectious mononucleosis, HIV, malaria, tuberculosis, histiocytosis, abscess).</p>
          </list-item>
          <list-item>
            <p>Connective tissue diseases (systemic lupus erythematosus, rheumatoid arthritis, Adult-onset Still's disease, and some familial autoinflammatory syndromes).<xref ref-type="bibr" rid="article-29386.r4">[4]</xref><xref ref-type="bibr" rid="article-29386.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Infiltrative disorders (sarcoidosis, amyloidosis, glycogen storage diseases).</p>
          </list-item>
          <list-item>
            <p>Splenic sequestration (pediatric sickle cell, hemolytic anemias, thalassemias).</p>
          </list-item>
          <list-item>
            <p>Focal lesions (hemangiomas, abscess, cysts, metastasis).</p>
          </list-item>
        </list>
        <p>The mechanism underlying splenic enlargement varies based on the etiology. In the case of acute infectious illness, the spleen performs increased work in clearing antigens and producing antibodies and&#x000a0;increases the number of reticuloendothelial cells contained within the spleen. These increased immune functions may result in splenic hyperplasia. In the case of liver disease and congestion, underlying illness causes increased venous pressure causing congestive splenomegaly. Extramedullary hematopoiesis exhibited in myeloproliferative disorders can lead to splenic enlargement (infiltrative splenomegaly).<xref ref-type="bibr" rid="article-29386.r6">[6]</xref><xref ref-type="bibr" rid="article-29386.r7">[7]</xref></p>
        <p>Splenic sequestration crisis (SSC) is a&#x000a0;life-threatening illness&#x000a0;common in&#x000a0;pediatric patients&#x000a0;with homozygous sickle cell disease and beta-thalassemia. Up to 30% of these children may develop SSC, with a&#x000a0;mortality rate&#x000a0;of up to 15%. This crisis&#x000a0;occurs&#x000a0;when splenic vaso-occlusion&#x000a0;causes&#x000a0;a large percentage of total blood volume&#x000a0;to become&#x000a0;trapped within the spleen. Clinical signs include&#x000a0;a severe, rapid drop in hemoglobin, leading to hypovolemic shock and death. Pediatric patients&#x000a0;with sickle cell disease and beta-thalassemia experience multiple splenic infarcts,&#x000a0;resulting in splenic fibrosis and scarring. Over time, this leads to a small, auto-infarcted spleen, typically by the time patients reach adulthood.&#x000a0;Splenic sequestration crisis can only occur in functioning spleens which may be why this crisis is rarely seen in adults. However, late adolescent or adult patients in this group who maintain splenic function may also develop a splenic sequestration crisis.</p>
      </sec>
      <sec id="article-29386.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Splenomegaly is a rare condition, with an estimated prevalence of approximately 2% of the total United States population. In adults, there has been no reported predominance in prevalence based on ethnicity, gender, or age. In Asia and Africa, tropical splenomegaly is very common.&#x000a0;In older people, the capsule of the spleen is thin, thus the risk of rupture is higher.</p>
      </sec>
      <sec id="article-29386.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Splenomegaly can be classified based on its pathophysiologic mechanism:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">Congestive</italic>, by pooled blood (e.g., portal hypertension)</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Infiltrative</italic>, by invasion by cells foreign to the splenic environment (eg., metastases, myeloid neoplasms, lipid storage diseases)</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Immune</italic>, by an increase in immunologic activity and subsequent hyperplasia (eg., endocarditis, sarcoidosis, rheumatoid arthritis)</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Neoplastic,</italic>&#x000a0;when resident immune cells originate a neoplasm (eg., lymphoma).</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29386.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The most common physical symptom associated with splenomegaly is vague abdominal discomfort. Patients may complain of pain in the left upper abdomen or referred pain in the left shoulder. Abdominal bloating, distended abdomen, anorexia, and/or early satiety may also occur. More commonly, patients&#x000a0;will present with symptoms due to the underlying illness causing splenomegaly. Constitutional symptoms such as weakness, weight loss, and night sweats suggest malignant illness. Patients with splenomegaly due to acute infection may present with fever, rigors, generalized malaise, or focal infectious symptoms. Patients with underlying liver disease may present with symptoms related to&#x000a0;cirrhosis or hepatitis. Symptoms of anemia (lightheadedness, dyspnea, or exertion), easy bruising, bleeding, or petechiae may indicate splenomegaly due to the underlying hemolytic process.</p>
        <p>Physical examination of the spleen is performed with the patient in supine and right lateral decubitus position with neck, hips, and knees flexed. This positioning relaxes the abdominal wall musculature and&#x000a0;rotates the spleen more anteriorly. Light fingertip pressure is applied below the left costal margin during deep inspiration. The examiner may feel the rounded edge of the spleen&#x000a0;pass underneath the fingertips at maximum inspiration. The exam is abnormal if the spleen is&#x000a0;palpated more than 2 cm below the costal margin. In massive splenomegaly, the spleen may be palpated deep into the abdomen, crossing the midline of the abdomen, and may even extend into the pelvis. Studies have shown that normal sized spleens may be palpable in approximately 3% of adults.</p>
        <p>Patients may&#x000a0;have an abnormally palpable spleen&#x000a0;with or without&#x000a0;exam findings of&#x000a0;contributing underlying illness. Patients with splenomegaly due to acute infection may have exam findings consistent with infectious mononucleosis, endocarditis, or malaria. Exam findings of petechiae, abnormal mucosal bleeding, or pallor may accompany hematologic diseases. Jaundice, hepatomegaly, ascites, or spider angiomata may be present in patients with liver disease. &#x000a0;Patients with rheumatologic diseases may present with joint tenderness, swelling, rash, or an abnormal lung exam.</p>
      </sec>
      <sec id="article-29386.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>A combination of serum testing and&#x000a0;imaging studies may definitively diagnose splenomegaly and the underlying cause. Derangement in the complete blood (cell) counts and morphology, including WBC, RBC, and platelets, will vary based on the underlying disease state.&#x000a0;Abnormalities in liver function tests, lipase, rheumatologic panels, and disease-specific infectious testing aid in the diagnosis of causative disease.<xref ref-type="bibr" rid="article-29386.r8">[8]</xref>&#x000a0;Hypersplenism may present with leukopenia, anemia, and thrombocytopenia.</p>
        <p>Imaging may be used to diagnose splenomegaly and elucidate its underlying cause. The spleen has a similar attenuation as the liver when measured on CT imaging. In addition to diagnosing splenomegaly (a splenic measurement of greater than 10 cm in craniocaudal length), abdominal CT may detect splenic abscess, mass lesions, vascular abnormalities, cysts, inflammatory changes, traumatic injury, intra-abdominal lymphadenopathy, or&#x000a0;liver abnormalities.</p>
        <p>Ultrasound is a useful imaging modality in measuring the spleen and spares the patient radiation from CT imaging. Normal spleen size measured via ultrasound is less than 13 cm superior to the inferior axis, 6 cm to 7 cm in the medial to lateral axis, and 5 cm to 6 cm in the anterior to posterior plane.</p>
        <p>MRI, PET scans, liver-spleen colloid scanning, splenectomy, and splenic biopsy may be indicated in certain cases.</p>
      </sec>
      <sec id="article-29386.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment of splenomegaly is targeted at treating the underlying disease and protecting the patient from complications of splenomegaly itself.&#x000a0; Patients with splenomegaly from any cause are at increased risk of splenic rupture, and increased attention must be made to protect the patient from abdominal trauma.&#x000a0;Treatment ranges from abdominal injury avoidance&#x000a0;in young healthy patients with splenomegaly due to infectious mononucleosis to splenectomy of a massively enlarged spleen in a patient with hairy cell leukemia. Likewise, the prognosis is largely dependent on the underlying disease state.<xref ref-type="bibr" rid="article-29386.r9">[9]</xref><xref ref-type="bibr" rid="article-29386.r10">[10]</xref></p>
        <p>Splenic sequestration is seen in sickle cell anemia is often managed with blood transfusions/exchange transfusions. Sometimes splenectomy is required for ITP. Low dose radiation therapy can also shrink the spleen size in patients with primary myelofibrosis.</p>
        <p>Patients who undergo splenectomy are at increased risk of infections secondary to encapsulated organisms such as <italic toggle="yes">Haemophilus Influenzae</italic>, <italic toggle="yes">Streptococcus pneumoniae</italic>, and <italic toggle="yes">Neisseria meningitidis. </italic>Vaccinations against these organisms are highly recommended in patients who have undergone splenectomy.&#x000a0;Careful attention must be paid to post-splenectomy patients presenting with febrile illnesses as they may require more aggressive, empiric antibiotic therapy.</p>
      </sec>
      <sec id="article-29386.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>There are several potential causes of splenomegaly, and careful and thorough evaluation is often needed to find the underlying cause of splenomegaly.</p>
        <p>These include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Cirrhosis</p>
          </list-item>
          <list-item>
            <p>Hepatitis</p>
          </list-item>
          <list-item>
            <p>Rheumatoid arthritis</p>
          </list-item>
          <list-item>
            <p>Felty syndrome</p>
          </list-item>
          <list-item>
            <p>Systemic lupus erythematosus</p>
          </list-item>
          <list-item>
            <p>Lymphoma</p>
          </list-item>
          <list-item>
            <p>Sickle cell anemia</p>
          </list-item>
        </list>
        <p>Liver disease (cirrhosis, hepatitis) is one of the most common causes, and a history of liver disease, abnormal physical exam findings, and elevated liver enzymes, in addition to abnormal liver imaging, can help diagnose liver diseases.</p>
        <p>Hematologic malignancies and metastasis shall be especially considered in patients with constitutional symptoms and weight loss. Abnormal peripheral blood smear and biopsy can assist in diagnosing malignancies.</p>
        <p>Autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) frequently are associated with splenomegaly. In RA, the presence of splenomegaly, in addition to neutropenia, is termed Felty syndrome.&#x000a0;</p>
        <p>Acute and chronic infections, including viral, bacterial, fungal, and mycobacterial infections, can all cause splenomegaly and shall be carefully ruled out.</p>
        <p>Cytopenias and diseases causing splenic sequestration can be ruled out by complete blood counts, peripheral blood smear, and hemoglobin electrophoresis.</p>
        <p>Infiltrative disorders such as&#x000a0;glycogen storage diseases are rare cause of splenomegaly and shall be considered if other more common causes are ruled out in patients with other clinical features consistent with these&#x000a0;glycogen storage diseases.</p>
      </sec>
      <sec id="article-29386.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis for patients with splenomegaly depends on the condition causing the enlargement. Regardless of the underlying etiology, the risk of rupture, even with minor trauma, is high in patients with an enlarged spleen.</p>
      </sec>
      <sec id="article-29386.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Splenic rupture is the most feared complication of splenomegaly. Patients are advised to avoid high-impact or contact sports to minimize this risk. Cytopenias due to splenomegaly are another potential complication. Most of these can be minimized with splenectomy if indicated.&#x000a0;</p>
      </sec>
      <sec id="article-29386.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients with enlarged spleens are advised to avoid high-impact or contact sports to avoid the risk of splenic rupture.&#x000a0;</p>
        <p>Once a patient undergoes splenectomy, they should be advised of the higher risk of infections, and proper immunization should take place to minimize this risk.&#x000a0;</p>
      </sec>
      <sec id="article-29386.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Patients with splenomegaly are best managed by an interprofessional team that includes a radiologist, internist, hematologist, oncologist, surgeon, nursing staff, and sometimes other specialists such as rheumatologists and gastroenterologists. Due to the high risk of rupture, patient education is crucial, and contact sports shall be avoided in patients with splenomegaly.&#x000a0;</p>
        <p>The nursing staff should educate the patient on the risk of infections if they undergo splenectomy. Vaccination against encapsulated organisms is highly recommended prior to the splenectomy.&#x000a0; All patients who have had a splenectomy should wear a medical alert bracelet explaining the absence of a spleen. Antibiotic prophylaxis is recommended in post-splenectomy patients undergoing surgical procedures. Further, careful attention must be paid to post-splenectomy patients presenting with febrile illnesses as they may require more aggressive, empiric antibiotic therapy.</p>
        <p>All patients with splenomegaly should be educated about the signs of splenic rupture and when to seek medical assistance. Unlike a normal spleen, an enlarged spleen that has ruptured cannot be managed with observation. Close collaboration with the team members is important to ensure that patients without a spleen have good outcomes.&#x000a0;Most patients have a good outcome after splenectomy.<xref ref-type="bibr" rid="article-29386.r11">[11]</xref><xref ref-type="bibr" rid="article-29386.r12">[12]</xref></p>
      </sec>
      <sec id="article-29386.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29386&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29386">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/gut-health/splenomegaly/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=29386">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/29386/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=29386">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-29386.s15">
        <fig id="article-29386.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Abdominal Radiograph of Splenomegaly. Splenomegaly is visualized on an abdominal x-ray. Contributed by S Dulebohn, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="splenomegaly_2" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-29386.s16">
        <fig id="article-29386.image.f2" position="float" orientation="portrait">
          <caption>
            <p>CT Splenomegaly Image courtesy O.Chaigasame</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Splenomegaly" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-29386.s17">
        <title>References</title>
        <ref id="article-29386.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nguyen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Stirnemann</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Belmatoug</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>[Gaucher disease: A review].</article-title>
            <source>Rev Med Interne</source>
            <year>2019</year>
            <month>May</month>
            <volume>40</volume>
            <issue>5</issue>
            <fpage>313</fpage>
            <page-range>313-322</page-range>
            <pub-id pub-id-type="pmid">30638965</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29386.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kang</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Clinical aspects of splenomegaly as a possible predictive factor of coronary artery changes in Kawasaki disease.</article-title>
            <source>Cardiol Young</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>297</fpage>
            <page-range>297-302</page-range>
            <pub-id pub-id-type="pmid">30572971</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29386.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gala</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Surapaneni</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Aziz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kallur</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>A Review of Outcomes in Pregnant Women with Portal Hypertension.</article-title>
            <source>J Obstet Gynaecol India</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>68</volume>
            <issue>6</issue>
            <fpage>447</fpage>
            <page-range>447-451</page-range>
            <pub-id pub-id-type="pmid">30416270</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29386.r4">
          <label>4</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Justiz Vaillant</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Goyal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Varacallo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Systemic Lupus Erythematosus</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>4</day>
            <pub-id pub-id-type="pmid">30571026</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29386.r5">
          <label>5</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Chauhan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jandu</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Brent</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Al-Dhahir</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <chapter-title>Rheumatoid Arthritis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">28723028</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29386.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palmiere</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tettamanti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Scarpelli</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Tse</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The forensic spleen: Morphological, radiological, and toxicological investigations.</article-title>
            <source>Forensic Sci Int</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>291</volume>
            <fpage>94</fpage>
            <page-range>94-99</page-range>
            <pub-id pub-id-type="pmid">30173072</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29386.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sjoberg</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Menias</surname>
                <given-names>CO</given-names>
              </name>
              <name>
                <surname>Lubner</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Mellnick</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Pickhardt</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Splenomegaly: A Combined Clinical and Radiologic Approach to the Differential Diagnosis.</article-title>
            <source>Gastroenterol Clin North Am</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>47</volume>
            <issue>3</issue>
            <fpage>643</fpage>
            <page-range>643-666</page-range>
            <pub-id pub-id-type="pmid">30115442</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29386.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Allison</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sunne</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Huntington</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Multifactorial Splenomegaly.</article-title>
            <source>S D Med</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>70</volume>
            <issue>12</issue>
            <fpage>535</fpage>
            <page-range>535-538</page-range>
            <pub-id pub-id-type="pmid">29334440</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29386.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saab</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Management of Thrombocytopenia in Patients with Chronic Liver Disease.</article-title>
            <source>Dig Dis Sci</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>64</volume>
            <issue>10</issue>
            <fpage>2757</fpage>
            <page-range>2757-2768</page-range>
            <pub-id pub-id-type="pmid">31011942</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29386.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kado</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McCune</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Treatment of primary and secondary immune thrombocytopenia.</article-title>
            <source>Curr Opin Rheumatol</source>
            <year>2019</year>
            <month>May</month>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>213</fpage>
            <page-range>213-222</page-range>
            <pub-id pub-id-type="pmid">30920453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29386.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vittorio</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Orellana</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ovchinsky</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Schlossberg</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Griesemer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lobritto</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Partial Splenic Embolization Is a Safe and Effective Alternative in the Management of Portal Hypertension in Children.</article-title>
            <source>J Pediatr Gastroenterol Nutr</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>68</volume>
            <issue>6</issue>
            <fpage>793</fpage>
            <page-range>793-798</page-range>
            <pub-id pub-id-type="pmid">30908386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29386.r12">
          <label>12</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Ashorobi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fernandez</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <chapter-title>Asplenia</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>11</month>
            <day>12</day>
            <pub-id pub-id-type="pmid">30844198</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
